Yutaka Oiso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yutaka Oiso has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Yasumasa Iwasaki
Department of Endocrinology, Metabolism, and Nephrology, Kochi Medical School, Kochi University, Nankoku, Japan
6 shared publications Hidehiko Saito
First Department of Internal Medicine (M.M., E.Y., A.N., N.M., M.Y., M.A., Y.O., H.S), Nagoya University School of Medicine, Nagoya 466-8550, Japan
3 shared publications- Hiroshi Arima
Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine
3 shared publications Hisashi Yokoi
First Department of Internal Medicine (S.K., T.M., H.A., H.Y., Y.M., Y.O.), Nagoya University School of Medicine, Showa-ku, Nagoya 466-8550, Japan
3 shared publications- Kazuki Fukuoka
Department of Endocrinology and Diabetes, Nagoya Ekisaikai Hospital, Nakagawawa-ku, Japan
3 shared publications Kunikazu Kondo
First Department of Internal Medicine, Nagoya University School of Medicine, Nagoya 466, Japan
3 shared publications
Latest Publications
- Open Access
- 1 January 2022
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 69 (11) , 1273-1279
Vasopressin, my best friend for life & Dr. Gary L. Robertson, the founder of the vasopressin world
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 1 January 2022
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 69 (11) , 1273-1279
Open AccessVasopressin, my best friend for life & Dr. Gary L. Robertson, the founder of the vasopressin world
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- Open Access
- 30 October 2015
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 15 (1) , 1-6
A novel loss-of-function mutation of GATA3 (p.R299Q) in a Japanese family with Hypoparathyroidism, Deafness, and Renal Dysplasia (HDR) syndrome
Hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome is a rare autosomal dominant disorder caused by mutations in the zinc finger transcription factor gene, GATA3. GATA3 has 2 zinc finger domains, which play an important role in the increase in target gene transcription activity. A 50-year-old woman and her 27-year-old daughter were followed up because of hypoparathyroidism. They had bilateral sensorineural deafness. Abdominal computed tomography scanning revealed renal dysplasia in the mother, but no renal anomaly in the daughter. Direct sequencing of GATA3 gene revealed a novel heterozygous missense mutation at codon 299 (p.R299Q) in exon 4. This mutation is located at the junction between the 2 zinc fingers. The structure prediction showed that it caused a conformation change in this junction area, affecting the spatial position of the zinc fingers. Additionally, a more marked conformation change was observed in the N-terminal zinc finger region compared to that in the C-terminal region. Functional analysis of this mutant protein using an in vitro luciferase reporter assay system confirmed that the mutation abolished the enhancing effects of wild-type GATA3 on the promoter activity of the consensus GATA responsive element and that of human PTH gene. We identified a novel R299Q mutation in GATA3 in a Japanese family with HDR syndrome. We confirmed that R299Q is a loss-of-function mutation, due to the extensive conformational change in the zinc fingers of GATA3.
- 30 October 2015
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 15 (1) , 1-6
Open AccessA novel loss-of-function mutation of GATA3 (p.R299Q) in a Japanese family with Hypoparathyroidism, Deafness, and Renal Dysplasia (HDR) syndrome
Hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome is a rare autosomal dominant disorder caused by mutations in the zinc finger transcription factor gene, GATA3. GATA3 has 2 zinc finger domains, which play an important role in the increase in target gene transcription activity. A 50-year-old woman and her 27-year-old daughter were followed up because of hypoparathyroidism. They had bilateral sensorineural deafness. Abdominal computed tomography scanning revealed renal dysplasia in the mother, but no renal anomaly in the daughter. Direct sequencing of GATA3 gene revealed a novel heterozygous missense mutation at codon 299 (p.R299Q) in exon 4. This mutation is located at the junction between the 2 zinc fingers. The structure prediction showed that it caused a conformation change in this junction area, affecting the spatial position of the zinc fingers. Additionally, a more marked conformation change was observed in the N-terminal zinc finger region compared to that in the C-terminal region. Functional analysis of this mutant protein using an in vitro luciferase reporter assay system confirmed that the mutation abolished the enhancing effects of wild-type GATA3 on the promoter activity of the consensus GATA responsive element and that of human PTH gene. We identified a novel R299Q mutation in GATA3 in a Japanese family with HDR syndrome. We confirmed that R299Q is a loss-of-function mutation, due to the extensive conformational change in the zinc fingers of GATA3.
- 1 January 2014
- Vol. 35 (5) , 342-6
An unusual case of hypopituitarism and transient thyrotoxicosis following asymptomatic pituitary apoplexy.
Although pituitary function is often impaired in pituitary apoplexy, the development of thyrotoxicosis is rare. We describe an unusual case of hypopituitarism due to pituitary apoplexy coexisting with transient hyperthyroidism. A 74-year-old woman presented with severe fatigue, palpitation, appetite loss, hypotension, and hyponatremia. Endocrine studies showed hyperthyroidism and anterior pituitary hormone deficiencies. A magnetic resonance imaging suggested recent-onset pituitary apoplexy in a pituitary tumor, although the patient had no apoplectic symptoms such as headache and visual disturbance. Thyrotoxicosis and adrenal insufficiency worsened her general condition. Glucocorticoid supplementation improved her clinical symptoms and hyponatremia. Serum anti-thyrotropin receptor and thyroid-stimulating antibody titers were negative, and her thyroid function was spontaneously normalized without antithyroid medication, suggesting painless thyroiditis. Thereafter, her thyroid function decreased because of central hypothyroidism and 75 µg of levothyroxine was needed to maintain thyroid function at the euthyroid stage. The pituitary mass was surgically removed and an old hematoma was detected in the specimen. Considering that painless thyroiditis develops as a result of an autoimmune process, an immune rebound mechanism due to adrenal insufficiency probably caused painless thyroiditis. Although the most common type of thyroid disorder in pituitary apoplexy is central hypothyroidism, thyrotoxicosis caused by painless thyroiditis should be considered even if the patient has pituitary deficiencies. Because thyrotoxicosis with adrenal insufficiency poses a high risk for a life-threatening adrenal crisis, prompt diagnosis and treatment are critical.
- 1 January 2014
- Vol. 35 (5) , 342-6
An unusual case of hypopituitarism and transient thyrotoxicosis following asymptomatic pituitary apoplexy.
Although pituitary function is often impaired in pituitary apoplexy, the development of thyrotoxicosis is rare. We describe an unusual case of hypopituitarism due to pituitary apoplexy coexisting with transient hyperthyroidism. A 74-year-old woman presented with severe fatigue, palpitation, appetite loss, hypotension, and hyponatremia. Endocrine studies showed hyperthyroidism and anterior pituitary hormone deficiencies. A magnetic resonance imaging suggested recent-onset pituitary apoplexy in a pituitary tumor, although the patient had no apoplectic symptoms such as headache and visual disturbance. Thyrotoxicosis and adrenal insufficiency worsened her general condition. Glucocorticoid supplementation improved her clinical symptoms and hyponatremia. Serum anti-thyrotropin receptor and thyroid-stimulating antibody titers were negative, and her thyroid function was spontaneously normalized without antithyroid medication, suggesting painless thyroiditis. Thereafter, her thyroid function decreased because of central hypothyroidism and 75 µg of levothyroxine was needed to maintain thyroid function at the euthyroid stage. The pituitary mass was surgically removed and an old hematoma was detected in the specimen. Considering that painless thyroiditis develops as a result of an autoimmune process, an immune rebound mechanism due to adrenal insufficiency probably caused painless thyroiditis. Although the most common type of thyroid disorder in pituitary apoplexy is central hypothyroidism, thyrotoxicosis caused by painless thyroiditis should be considered even if the patient has pituitary deficiencies. Because thyrotoxicosis with adrenal insufficiency poses a high risk for a life-threatening adrenal crisis, prompt diagnosis and treatment are critical.
- 30 September 2011
- Published by Elsevier in Neuroscience Research
- Vol. 71, e223
Pathway analysis of single-microglia gene-expression profiles reveals the new molecular targets of minocycline treatment
- 30 September 2011
- Published by Elsevier in Neuroscience Research
- Vol. 71, e223
Pathway analysis of single-microglia gene-expression profiles reveals the new molecular targets of minocycline treatment
- 30 September 2011
- Published by Elsevier in Neuroscience Research
- Vol. 71, e365
Proteomic analysis for identifying the pathogenic autoantigen of isolated adrenocorticotropin (ACTH) deficiency and lymphocytic adenohypophysitis
- 30 September 2011
- Published by Elsevier in Neuroscience Research
- Vol. 71, e365
Proteomic analysis for identifying the pathogenic autoantigen of isolated adrenocorticotropin (ACTH) deficiency and lymphocytic adenohypophysitis
- Open Access
- 1 December 2000
- Published by The Endocrine Society in Endocrinology
- Vol. 141 (12) , 4466-4471
Role of Endogenous Nociceptin in the Regulation of Arginine Vasopressin Release in Conscious Rats
The effects of central administration of the opioid-like peptide nociceptin (also known as orphanin FQ) were investigated on the secretion of arginine vasopressin (AVP) in response to dehydration and hyperosmolar or hypovolemic stimulation in conscious rats. Intracerebroventricular (icv) administration of nociceptin suppressed plasma AVP concentration in a dose-dependent manner (0.1–10 μg/rat) in dehydrated rats, and the maximum effect was obtained 10 min after the administration (dehydration with 10 μg/rat nociceptin, 3.11± 0.27 pg/ml vs. control, 10.32 ± 0.96 pg/ml). The plasma AVP increase in response to either hyperosmolality [ip injection of hypertonic saline (HS) (600 mosml/kg)] or hypovolemia[ ip injection of polyethylene glycol (PEG)] was also significantly blunted when nociceptin was injected icv (HS with 10 μg/rat nociceptin, 1.16 ± 0.09 pg/ml vs. control, 1.82 ± 0.30 pg/ml; PEG with 10 μg/rat nociceptin, 0.91 ± 0.16 pg/ml vs. control, 2.41 ± 0.26 pg/ml). Pretreatment with a selective opioid κ-receptor antagonist, nor-binaltorphimine (1 μg/rat, icv) or naloxone (2.5 mg/rat, sc injection) did not reverse the inhibitory effects of nociceptin on AVP release. Moreover, when plasma AVP was suppressed by acute water loading, immunoneutralization of endogenous nociceptin by antinociceptin-antiserum icv significantly reversed the suppression (0.57 ± 0.12 pg/ml vs. control, 0.25 ± 0.04 pg/ml). These results suggest that central nociceptin is physiologically involved in the control of AVP release through an inhibitory action.
- 1 December 2000
- Published by The Endocrine Society in Endocrinology
- Vol. 141 (12) , 4466-4471
Open AccessRole of Endogenous Nociceptin in the Regulation of Arginine Vasopressin Release in Conscious Rats
The effects of central administration of the opioid-like peptide nociceptin (also known as orphanin FQ) were investigated on the secretion of arginine vasopressin (AVP) in response to dehydration and hyperosmolar or hypovolemic stimulation in conscious rats. Intracerebroventricular (icv) administration of nociceptin suppressed plasma AVP concentration in a dose-dependent manner (0.1–10 μg/rat) in dehydrated rats, and the maximum effect was obtained 10 min after the administration (dehydration with 10 μg/rat nociceptin, 3.11± 0.27 pg/ml vs. control, 10.32 ± 0.96 pg/ml). The plasma AVP increase in response to either hyperosmolality [ip injection of hypertonic saline (HS) (600 mosml/kg)] or hypovolemia[ ip injection of polyethylene glycol (PEG)] was also significantly blunted when nociceptin was injected icv (HS with 10 μg/rat nociceptin, 1.16 ± 0.09 pg/ml vs. control, 1.82 ± 0.30 pg/ml; PEG with 10 μg/rat nociceptin, 0.91 ± 0.16 pg/ml vs. control, 2.41 ± 0.26 pg/ml). Pretreatment with a selective opioid κ-receptor antagonist, nor-binaltorphimine (1 μg/rat, icv) or naloxone (2.5 mg/rat, sc injection) did not reverse the inhibitory effects of nociceptin on AVP release. Moreover, when plasma AVP was suppressed by acute water loading, immunoneutralization of endogenous nociceptin by antinociceptin-antiserum icv significantly reversed the suppression (0.57 ± 0.12 pg/ml vs. control, 0.25 ± 0.04 pg/ml). These results suggest that central nociceptin is physiologically involved in the control of AVP release through an inhibitory action.
- Open Access
- 1 September 2000
- Published by The Endocrine Society in Endocrinology
- Vol. 141 (9) , 3313-3318
Antidiabetic Sulfonylurea Enhances Secretagogue-Induced Adrenocorticotropin Secretion and Proopiomelanocortin Gene Expression in Vitro
The presence of high-affinity binding sites for antidiabetic sulfonylureas (SUs) and the expression of SU receptor (SUR) messenger RNA in the adenohypophyseal cells have recently been reported. In this study, we examined the effects of SU on POMC gene expression and ACTH secretion using the AtT20PL cell line, a subclone of AtT20 in which the rat POMC 5′-promoter-luciferase fusion gene was stably incorporated. A representative SU glibenclamide inhibited the basal POMC 5′-promoter activity. In contrast, glibenclamide enhanced forskolin- or CRH-induced POMC expression in a dose-dependent manner. Interestingly, the latter effect was not observed under treatment with 3-isobutyl-1-methylxanthine, a nonselective phosphodiesterase inhibitor. Furthermore, diazoxide, an opener of the ATP-sensitive K+ channel, only antagonized the suppressive effect of glibenclamide. Lastly, RT-PCR analysis showed that mouse SUR (but not SUR2) messenger RNA was expressed in this cell line. These results suggest that, in AtT20PL cells, SU has dual effects, i.e. a suppressive effect on basal POMC expression through diazoxide-sensitive (ATP-sensitive) K+-channel-mediated mechanism, and an enhancing effect on cAMP/protein kinase A-stimulated POMC expression through a different mechanism (probably mediated by phosphodiesterase). To our knowledge, this is the first report showing the effect of SU on the expression of the anterior pituitary hormone gene.
- 1 September 2000
- Published by The Endocrine Society in Endocrinology
- Vol. 141 (9) , 3313-3318
Open AccessAntidiabetic Sulfonylurea Enhances Secretagogue-Induced Adrenocorticotropin Secretion and Proopiomelanocortin Gene Expression in Vitro
The presence of high-affinity binding sites for antidiabetic sulfonylureas (SUs) and the expression of SU receptor (SUR) messenger RNA in the adenohypophyseal cells have recently been reported. In this study, we examined the effects of SU on POMC gene expression and ACTH secretion using the AtT20PL cell line, a subclone of AtT20 in which the rat POMC 5′-promoter-luciferase fusion gene was stably incorporated. A representative SU glibenclamide inhibited the basal POMC 5′-promoter activity. In contrast, glibenclamide enhanced forskolin- or CRH-induced POMC expression in a dose-dependent manner. Interestingly, the latter effect was not observed under treatment with 3-isobutyl-1-methylxanthine, a nonselective phosphodiesterase inhibitor. Furthermore, diazoxide, an opener of the ATP-sensitive K+ channel, only antagonized the suppressive effect of glibenclamide. Lastly, RT-PCR analysis showed that mouse SUR (but not SUR2) messenger RNA was expressed in this cell line. These results suggest that, in AtT20PL cells, SU has dual effects, i.e. a suppressive effect on basal POMC expression through diazoxide-sensitive (ATP-sensitive) K+-channel-mediated mechanism, and an enhancing effect on cAMP/protein kinase A-stimulated POMC expression through a different mechanism (probably mediated by phosphodiesterase). To our knowledge, this is the first report showing the effect of SU on the expression of the anterior pituitary hormone gene.
- Open Access
- 1 May 1998
- Published by The Endocrine Society in Endocrinology
- Vol. 139 (5) , 2414-2422
Cytokine Regulation of the Rat Proopiomelanocortin Gene Expression in AtT-20 Cells
Although cytokines are known to be involved in the regulation of ACTH secretion, their effects, along with the molecular mechanisms, on POMC gene expression are not thoroughly characterized. In this study we examined the effects of representative cytokines on transcription of the POMC gene in corticotrophs in vitro using AtT20PL, a clone of the AtT20 cell line stably transfected with approximately 0.7 kilobase of the rat POMC 5′-promoter-luciferase fusion gene. In each experiment, cells were incubated with the cytokine tested, and the changes in POMC 5′-promoter activity were determined by a luciferase assay. The results showed that interleukin-1β (IL-1β) stimulated promoter activity in a biphasic manner [weak short term effects (2–3 h) followed by potent long term effects (>12–16 h)]. Tumor necrosis factor-α had similar effects, but much less potency. IL-6 showed a profound stimulatory, but only a long term (>20 h), effect. IL-2 did not influence POMC expression. In contrast, interferon-α (IFNα) and IFN-γ showed acute stimulatory effects (∼4 h) followed by marked inhibitory effects (>8 h). Although the acute effects of IL-1β, IL-6, and tumor necrosis factor-α alone were minimal, they significantly potentiated the stimulatory effect of CRH on POMC expression. Finally, pretreatment of the cells with a broad spectrum tyrosine kinase inhibitor, genistein, abolished or significantly diminished the effects of all cytokines except IFNs. Our results suggest that 1) each cytokine tested has a distinct effect on POMC gene expression; 2) there are positive cross-talk effects between CRH and cytokines at the corticotroph level; and 3) tyrosine phosphorylation cascades are involved in the intracellular signaling mechanisms of some cytokines.
- 1 May 1998
- Published by The Endocrine Society in Endocrinology
- Vol. 139 (5) , 2414-2422
Open AccessCytokine Regulation of the Rat Proopiomelanocortin Gene Expression in AtT-20 Cells
Although cytokines are known to be involved in the regulation of ACTH secretion, their effects, along with the molecular mechanisms, on POMC gene expression are not thoroughly characterized. In this study we examined the effects of representative cytokines on transcription of the POMC gene in corticotrophs in vitro using AtT20PL, a clone of the AtT20 cell line stably transfected with approximately 0.7 kilobase of the rat POMC 5′-promoter-luciferase fusion gene. In each experiment, cells were incubated with the cytokine tested, and the changes in POMC 5′-promoter activity were determined by a luciferase assay. The results showed that interleukin-1β (IL-1β) stimulated promoter activity in a biphasic manner [weak short term effects (2–3 h) followed by potent long term effects (>12–16 h)]. Tumor necrosis factor-α had similar effects, but much less potency. IL-6 showed a profound stimulatory, but only a long term (>20 h), effect. IL-2 did not influence POMC expression. In contrast, interferon-α (IFNα) and IFN-γ showed acute stimulatory effects (∼4 h) followed by marked inhibitory effects (>8 h). Although the acute effects of IL-1β, IL-6, and tumor necrosis factor-α alone were minimal, they significantly potentiated the stimulatory effect of CRH on POMC expression. Finally, pretreatment of the cells with a broad spectrum tyrosine kinase inhibitor, genistein, abolished or significantly diminished the effects of all cytokines except IFNs. Our results suggest that 1) each cytokine tested has a distinct effect on POMC gene expression; 2) there are positive cross-talk effects between CRH and cytokines at the corticotroph level; and 3) tyrosine phosphorylation cascades are involved in the intracellular signaling mechanisms of some cytokines.
- Open Access
- 1 April 1998
- Published by The Endocrine Society in Endocrinology
- Vol. 139 (4) , 1481-1486
Regulation of Vasopressin Synthesis and Release by Area Postrema in Rats
There is evidence indicating that the area postrema (AP), the most caudal circumventricular organ located on the dorsal surface of the medulla, is involved in several physiological regulations. In this study, we investigated the role of AP in the regulation of arginine vasopressin (AVP) synthesis and release, using rats of which the AP was lesioned 6 weeks previously. The level of plasma AVP in the AP lesioned (APX) group was significantly lower than in the sham operated (Sham) group in the basal state. AVP release induced by either hyperosmolality or hypovolemia was significantly attenuated by APX. To clarify the role of AP in AVP synthesis in the hypothalamus, we examined the AVP gene expression using in situ hybridization. AVP messenger RNA levels in paraventricular (PVN) and supraoptic nuclei (SON) in the APX group were significantly lower than in the Sham group in the basal state. Moreover, the AVP messenger RNA levels in PVN and SON in the APX group were also significantly lower than in the Sham group after water deprivation for 3 days. These results suggest that AVP synthesis and release are tonically stimulated by AP in the basal state and that AVP synthesis and release in stimulated states are also regulated, at least partially, by AP.
- 1 April 1998
- Published by The Endocrine Society in Endocrinology
- Vol. 139 (4) , 1481-1486
Open AccessRegulation of Vasopressin Synthesis and Release by Area Postrema in Rats
There is evidence indicating that the area postrema (AP), the most caudal circumventricular organ located on the dorsal surface of the medulla, is involved in several physiological regulations. In this study, we investigated the role of AP in the regulation of arginine vasopressin (AVP) synthesis and release, using rats of which the AP was lesioned 6 weeks previously. The level of plasma AVP in the AP lesioned (APX) group was significantly lower than in the sham operated (Sham) group in the basal state. AVP release induced by either hyperosmolality or hypovolemia was significantly attenuated by APX. To clarify the role of AP in AVP synthesis in the hypothalamus, we examined the AVP gene expression using in situ hybridization. AVP messenger RNA levels in paraventricular (PVN) and supraoptic nuclei (SON) in the APX group were significantly lower than in the Sham group in the basal state. Moreover, the AVP messenger RNA levels in PVN and SON in the APX group were also significantly lower than in the Sham group after water deprivation for 3 days. These results suggest that AVP synthesis and release are tonically stimulated by AP in the basal state and that AVP synthesis and release in stimulated states are also regulated, at least partially, by AP.
- 20 September 1996
- Published by Elsevier in Neuroscience Letters
- Vol. 216 (1) , 65-67
Intracerebroventricular injection of adrenomedullin inhibits vasopressin release in conscious rats
- 20 September 1996
- Published by Elsevier in Neuroscience Letters
- Vol. 216 (1) , 65-67
Intracerebroventricular injection of adrenomedullin inhibits vasopressin release in conscious rats